Cargando…
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
PURPOSE: The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing. METHODS: Model si...
Autores principales: | Lu, Dan, Lu, Tong, Shi, Rong, Gibiansky, Leonid, Agarwal, Priya, Shemesh, Colby S., Dere, Randall C., Ogbu, Uzor, Hirata, Jamie, Chanu, Pascal, Girish, Sandhya, Jin, Jin Yan, Li, Chunze, Miles, Dale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708381/ https://www.ncbi.nlm.nih.gov/pubmed/33258982 http://dx.doi.org/10.1007/s11095-020-02933-6 |
Ejemplares similares
-
Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019) -
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020) -
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Shi, Rong, et al.
Publicado: (2020) -
Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Dere, Randall C., et al.
Publicado: (2023) -
Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)